Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Biogen announced topline results from the Phase III VALOR trial of tofersen for superoxide dismutase 1 amyotrophic lateral sclerosis.
The FDA reviewed Tecentriq under Project Orbis, allowing the simultaneous submission and review of potential oncology treatments to international regulatory bodies.
Cartesian’s Descartes-08 is a new chimeric antigen receptor (CAR) - T cell therapy that strives to target the myasthenia gravis disease at its source.
Biopharma companies recognized that developing a therapy is merely the beginning of what is needed to connect patients with sickle cell disease to next-level therapies.
The U.S. Food and Drug Administration has a few PDUFA dates on its calendar for this week. Here’s a look.
The advisory committee voted 19-0 to recommend the extra dose of the J&J shot for anyone 18 years and older.
Read about TFF Pharmaceuticals and Augmenta Bioworks’ dry powder COVID-19 antibody formula, the world’s first gene editing clinical trial for PKU, Bayer’s COVID-19 vaccine and other key developments in life sciences research.
The project will be one of the largest construction projects in North Carolina, with about 2 million sq. ft. of space. It is expected to bring in 725 new jobs in Wake County over the next five years.
Facing thousands of lawsuits related to its talc-based products, life sciences giant Johnson & Johnson is launching a separate subsidiary dubbed LTL Management LLC that will take the brunt of potential legal liabilities.
It was yet another busy week for clinical trial announcements. Take a look.
The FDA and Regeneron are reportedly in talks to set up an advisory committee meeting to discuss the BLA ahead of the target action date.
The 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis ran from October 13 to 15, with companies globally presenting cutting-edge studies on MS.